NCT01562977

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Apr 1, 2011
Primary completion: Apr 1, 2015
Completion date: Apr 1, 2017
First posted: —
Last posted: —
Enrollment: 129
Arms / groups: 1 / —
Source: AACT · pre-existing

Sponsors

Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaLead sponsor
University of ZaragozaOverall official - principal investigator
Hospital Son EspasesOverall official - principal investigator
Fundación Hospital AlcorcónOverall official - principal investigator
University of ValenciaOverall official - principal investigator
Hospital Virgen de la ConchaOverall official - principal investigator
Hospital Dr. Jose Molina OrosaOverall official - principal investigator
Hospital Morales MeseguerOverall official - principal investigator
Hospital Duran i ReynalsOverall official - principal investigator
University of SantiagoOverall official - principal investigator
Hospital del SAS de JerezOverall official - principal investigator
University of BarcelonaOverall official - principal investigator
Universidad de MurciaOverall official - principal investigator
Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaReponsible party - principal investigator
Universidad Autonoma de MadridOverall official - principal investigator
Universidad Complutense de MadridOverall official - principal investigator
Badalona Hospital Germans Trias i PujolOverall official - principal investigator
University of Las Palmas de Gran CanariaOverall official - principal investigator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.